TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PGE1 as Additive Anticoagulant in ECMO-Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* minimum age 18 years~  * Veno-Venous- ECMO~ * Minimum of 24h planned ECMO- therapy~Exclusion Criteria:~* • Long- term therapy with other antiplatelet drugs including Acetyl Salicylic Acid~  * known Heparin induced thrombocytopenia~ * Bleeding diathesis = contraindication for heparin (e.g. GI-bleeding, Intracerebral bleeding)~ * Platelets \< 50 G/L~ * Thromboplastin time \< 50%~ * Pregnancy~ * Patient \< 18 years~ * prothrombin time \<50%~Drop out criteria:~* Major bleeding (from Type 3 bleeding; see primary objective)~* Occurrence of HIT (4 T- Score: Number of platelets, development over time, manifestation of thrombosis, other reasons for thrombocytopenia \[10\])~* Plt \< 50 G/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alprostadil (Type: EXPERIMENTAL): heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
- Placebo (Type: PLACEBO_COMPARATOR): heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children that have been identified to need a voiding cystourethrogram~Exclusion Criteria:~* Significant medical conditions that preclude child from being able to understand play therapy or have been identified in the past to have so much discomfort from prior studies as to not be able to participate.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- No intervention (Type: NO_INTERVENTION): Parents given routine information by the medical staff.
- Parental information (Type: ACTIVE_COMPARATOR): Parents are provided with an educational brochure of the study and the expectations of the discomfort.
- Play Therapy (Type: ACTIVE_COMPARATOR): Child and the parents will spend time in the office with the child life therapist undergoing play therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* OMS grade II glioma~* signed informed consent~* age \>=18~* IK \>=80%~* ability to read, write and undertand French~Exclusion Criteria:~* glioma localized to brainstem~* other neurologic or psychiatric disease~* history of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization~* neuroleptic concomitant treatment~* pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OMS grade II glioma (Type: OTHER): neurocognitive tests

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blending Two Worlds: Traditional Aboriginal Healing Strategies for Depression and Anxiety

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* children and adolescents (less than 18 years of age)and families with anxiety and/or depression attending the Surrey North Child and Youth Mental Health Team.~Exclusion Criteria:~* Subjects with severe anxiety or depression requiring intervention (i.e. hospitalization) or have a past or present history of suicide attempt. Subjects with special needs including medical contraindications (i.e. medical conditions including pregnancy), brain injury, developmental disability or fetal alcohol syndrome). Those subjects unwilling or unable to participate in a Traditional Healing options.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Traditional Healing arm Provides Traditional Healing options only
- 3 (Type: ACTIVE_COMPARATOR): Traditional Healing and usual standard of care arm Subjects will access both treatment options
- 1 (Type: ACTIVE_COMPARATOR): Treatment as usual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Myocardial Stress Perfusion Computed Tomography in the Evaluation of Patients With Acute Chest Pain Using a Novel 3rd Generation Dual-source CT System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must present with symptoms of acute but atypical or recurrent chest pain.~* Subject must have been referred for cardiac CT angiography OR subject must have undergone clinically indicated SPECT with positive or equivocal findings OR subject must have undergone clinically indicated SPECT with prior cardiac CT angiography that showed moderate or severe stenosis.~* Subject must be 18-85 years of age.~* Subject must provide written informed consent prior to any study-related procedures being conducted.~* Subject must be willing to comply with all clinical study procedures.~Exclusion Criteria:~* Subject is a pregnant or nursing female.~* Subject has severe asthma or COPD requiring frequent inhaler use.~* Subject has prior diagnosis of obstructive CAD that has not been revascularized.~* Subject with implanted rhythm devices (pacemaker, defibrillator).~* Subject has significant arrhythmia.~* Subject has high grade heart block.~* Subject has resting heart rate \< 45 bpm, systolic blood pressure \<90 mm Hg, or has consumed caffeine within the last 12 hours.~* Subject has an acute psychiatric disorder.~* Subject is unwilling to comply with the requirements of the protocol.~* Subject has previously entered this study.~* Subject has an allergy against iodinated contrast or pharmaceutical stressors used in this study.~* Subject suffers from claustrophobia.~* Subject has impaired renal function (creatinine \> 1.5 mg/dl).~* Subject is in unstable condition.~* ST-elevations, new transient ST changes greater than 0.05mV or T-wave inversions with symptoms.~* Subject cannot safely be administered Lexiscan per prescribing information as as determined by investigator.~* Subject has received interventional (PCI, stenting) or surgical (CABG) treatment that may alter the cardiac condition regarding myocardial perfusion status and/or stenosis degree between cardiac CTA, SPECT, and/or CT stress perfusion studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Myocardial Stress CT Perfusion (Type: EXPERIMENTAL): Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form.~* Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria~* Minimum of 3 years since diagnosis.~* Meet Hoehn and Yahr PD stage~* Good response to levodopa~* Stable regimen of anti-PD medications~* Patients must have been taking a levodopa-containing anti-PD medication continuously for at least the previous 12 months~* Patient has documented a minimum amount of Off time.~* If of childbearing potential (male and female) must use an acceptable method of contraception~Exclusion Criteria:~* Previous tozadenant study participation~* Current or recent participation in another study.~* Secondary or atypical parkinsonism~* Neurosurgical intervention for PD~* Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®~* Treatment with excluded medications~* Untreated or uncontrolled hyperthyroidism or hypothyroidism~* Clinically significant out-of-range laboratory~* MMSE out of range~* Current episode of major depression (stable treatment for depression is permitted).~* Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS)~* Women lactating or pregnant~* Hypersensitivity to any components of tozadenant or excipients~* Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study~* History of hepatitis or cholangitis

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tozadenant 60 mg BID (Type: EXPERIMENTAL): During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B.
- Tozadenant 120 mg BID (Type: EXPERIMENTAL): During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B.
- Placebo BID (Type: PLACEBO_COMPARATOR): During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, through the ages of 18 and 55 years, inclusive.~Exclusion Criteria:~* Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures.~* Subjects who are displaying clinically significant homicidality or suicidality~* Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. Subjects should be biochemically euthyroid to enter the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Lisdexamfetamine (Type: ACTIVE_COMPARATOR): Drug
- Placebo (Type: PLACEBO_COMPARATOR): Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Determining Risk Factors for Successful PPI Weaning

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old~* Male or female~* PPI on home medication reconciliation~* GERD that is symptom controlled (per questionnaire), OR~* Gastritis that is symptom controlled (per questionnaire), OR~* An unclear indication for PPI use but free of GERD/gastritis/ulcer symptoms (includes patients on GI prophylaxis from the hospital and continued medication)~* Desire or willingness to be off of PPI chronically~* On PPI chronically (\> 2 months or 8 weeks, can be intermittent use)~* Initial PPI dose cannot exceed more than the equivalent of Omeprazole 40mg PO BID~* Comprehend English well (per provider's discretion; to understand questionnaires, instructions, etc.)~Exclusion Criteria:~* On PPI for fewer than 2 months~* Co-morbid diagnosis of Peptic Ulcer Disease, H.pylori infection, Barrett's esophagus, malignancy, Inflammatory Bowel Disease~* Diagnosis of moderate to severe renal impairment (defined as CrCl \<50 mL/min; reasoning due to caution of H2RB on renal failure)~* Diagnosis of prolonged QT interval with renal impairment (reasoning due to H2RB with concomitant renal failure may increase QT interval if not renally dosed)~* True allergy to Proton Pump Inhibitor and / or H2 Receptor Blocker~* Patients with frequent cardiac angina symptoms (decreasing the dose of PPI may cause rebound GERD and the patient may think they are having a heart attack)~* Pregnant women, fetuses, neonates or fetal material~* Females of reproductive potential at time of research that are not on a form on birth control (OCPs, tubal ligation, etc) or lactating~* Adults with decisional impairment~* Prisoners~* Patients with uncontrolled Psychological illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PPI Taper (Type: OTHER): PPI Taper using Lifestyle Modifications, per study protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Neurogenic Incontinence by Surgery to Cut the Filum Terminale

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary or secondary daytime urinary incontinence, persistent over at least 6 months of medical treatment.~* Abnormal urodynamic testing~* Normal conus on magnetic resonance imaging of the spine~* Dysfunctional Voiding Symptom Scale score greater than 6 for girls or greater than 9 for boys~Exclusion Criteria:~* Bladder outlet obstruction~* Bladder atony~* Congenital anorectal malformation~* Additional diagnoses independently associated with neurogenic bladder dysfunction~* Encephalopathy precluding reasonable expectation of attainment of continence~* Inability to comply with medical management~* Unwillingness to comply with initial or follow up urodynamic testing

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Neurogenic incontinence (Type: None): The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of primary peritoneal carcinoma, fallopian tube epithelial ovarian carcinoma,~* stage III suboptimal surgery or biopsy,~* stage IV disease~* no prior chemotherapy~Exclusion Criteria:~* unstable heart conditions~* high blood pressure~* vascular disorders~* bleeding problems

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Short-term Comparative Study of Aerosure for Airway Clearance in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of CF (established by genotype or sweat sodium \>70mmol/l or sweat chloride of \>60 mmol/l~* Admitted to King's College Hospital within 48 hours of an acute infective pulmonary exacerbation characterised by an increase in respiratory symptoms requiring intravenous antibiotics~Exclusion Criteria:~* Acute respiratory failure~* Haemodynamic instability (including severe right heart failure with hypotension)~* Current severe haemoptysis~* Ineffective cough~* Rib fractures~* Pregnancy~* Current or recent pneumothorax~* Epilepsy~* Current pulmonary embolism~* Oesophageal varices~* Recent thoracic upper gastro-intestinal tract or facial surgery~* Active tuberculosis~* Recent brain, eye, ear, ENT surgery~* Myocardial infarction~* Ascending aortic aneurysm~* Acute diarrhoea~* Pulmonary embolism~* Angina~* Severe hypertension (systolic \>200 mm Hg, diastolic \>120 mm Hg)~* Confusion/dementia~* Inability to give consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aerosure 15 Hz (Type: EXPERIMENTAL): All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised.
- Aerosure 25 Hz (Type: ACTIVE_COMPARATOR): All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure.
- Aerosure sham (Type: SHAM_COMPARATOR): All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate if the Medication Gabapentin Lessens Vulvar Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women, ages 18 years and older with the diagnosis of vulvodynia or VVS (by Friedrich's criteria), who present to the University of Iowa Vulvar Vaginal Disease Clinic.~Exclusion Criteria:~* Vulvar Vaginal Disease clinic patients who are pregnant, less than 3 months postpartum, breast-feeding, non-English speaking, or have contraindication to use of gabapentin due to allergy or renal disease (serum creatinine level greater than 1.4).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Gabapentin (Type: ACTIVE_COMPARATOR): Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
- Placebo oral capsule (Type: PLACEBO_COMPARATOR): Placebo titration and dosing for total of 8 weeks (Cross over)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient- and Task-specific Radiation Dose Optimization for Pediatric Abdominopelvic CT Applications

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-~Exclusion Criteria:~* Pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Dose Split CT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues